Tucidinostat - HUYA Bioscience International

Drug Profile

Tucidinostat - HUYA Bioscience International

Alternative Names: Chidamide; CS-055; Epidaza; HBI-8000

Latest Information Update: 01 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chipscreen Biosciences
  • Developer Chipscreen Biosciences; Guangxi Center for Disease Control and Prevention; HUYA Bioscience International; Quintiles; Zhejiang University
  • Class Aminopyridines; Antineoplastics; Benzamides; Small molecules
  • Mechanism of Action Apoptosis stimulants; CD244 antigen modulators; CD8 positive T lymphocyte stimulants; Histone deacetylase inhibitors; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T cell lymphoma; Peripheral T-cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Peripheral T-cell lymphoma
  • Phase III Breast cancer
  • Phase II/III Cutaneous T cell lymphoma; HIV infections
  • Phase II Adult T-cell leukaemia-lymphoma; Non-small cell lung cancer
  • Phase I/II Solid tumours
  • Phase I Non-Hodgkin's lymphoma

Most Recent Events

  • 02 Jun 2017 Efficacy, safety and pharmacokinetics data from a phase III trial in Breast cancer presented at 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 19 Apr 2017 GNT Biotech & Medicals Corporation intends to submit a NDA application for Breast cancer in Taiwan in 2019
  • 19 Apr 2017 The Taiwan Food and Drug Administration approves IND application for tucidinostat in Breast cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top